- Home
- FANG vs EW Comparison
FANG vs EW Comparison
Compare FANG & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FANG | EW |
|---|---|---|
| Founded | 2007 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Industrial Specialties |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3B | 45.5B |
| IPO Year | 2012 | 2000 |
Fundamental Metrics
Financial Performance| Metric | FANG | EW |
|---|---|---|
| Price | $158.60 | $86.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 21 |
| Target Price | ★ $186.61 | $94.68 |
| AVG Volume (30 Days) | 1.6M | ★ 3.4M |
| Earning Date | 11-03-2025 | 10-30-2025 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 14.37 | 2.33 |
| Revenue | ★ $14,626,000,000.00 | $5,883,800,000.00 |
| Revenue This Year | $43.41 | $14.26 |
| Revenue Next Year | N/A | $9.77 |
| P/E Ratio | ★ $11.04 | $37.01 |
| Revenue Growth | ★ 59.73 | 10.60 |
| 52 Week Low | $114.00 | $65.94 |
| 52 Week High | $180.91 | $87.89 |
Technical Indicators
Market Signals| Indicator | FANG | EW |
|---|---|---|
| Relative Strength Index (RSI) | 67.71 | 59.20 |
| Support Level | $143.57 | $83.60 |
| Resistance Level | $158.73 | $87.40 |
| Average True Range (ATR) | 4.62 | 1.76 |
| MACD | 1.16 | -0.28 |
| Stochastic Oscillator | 72.03 | 63.57 |
Price Performance
Historical ComparisonAbout FANG Diamondback Energy Inc.
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2024, the company reported net proven reserves of 3.6 billion barrels of oil equivalent. Net production averaged about 598,000 barrels per day in 2024, at a ratio of 56% oil, 23% natural gas liquids, and 21% natural gas.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.